Jazz to Withdraw Zepzelca Second-Line Use After Failed Trial
JAZZ has more than doubled off its 52-week low of $105.
Summary
Jazz Pharmaceuticals will ask the FDA to pull Zepzelca's second-line small cell lung cancer indication, following the Phase 3 LAGOON trial failure reported in June. The first-line maintenance indication, which drove 42% Zepzelca growth last quarter, is unaffected. The withdrawal formalizes the negative trial outcome and removes a revenue stream, though the drug's primary growth driver remains intact. The labeling supplement is expected in Q3. This follows the strong Q2 beat yesterday, where Zepzelca's first-line launch was the highlight.
At the time of this announcement, JAZZ was trading at $256.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $105.00 to $261.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.